• Mashup Score: 0

    In this episode, hosts discuss their experience interacting with the Tandem Mobi pump from the ADCES 2023 meeting and offer perspective on what the Welldoc clearances mean for people with diabetes and care providers.

    Tweet Tweets with this article
    • The latest #DiabetesDialogue features a discussion on the @TandemDiabetes Mobi insulin pump and the FDA clearance of @Welldoc's BlueStar. https://t.co/8GNJvCFEci #Diabetes @DianaMIsaacs @natalie_bellini https://t.co/WO6XQx5kYj

  • Mashup Score: 0

    In this episode, hosts discuss their experience interacting with the Tandem Mobi pump from the ADCES 2023 meeting and offer perspective on what the Welldoc clearances mean for people with diabetes and care providers.

    Tweet Tweets with this article
    • Check out the latest episode of #DiabetesDialogue where hosts discuss the @TandemDiabetes Mobi insulin pump and the FDA clearance of the BlueStar platform from @Welldoc. https://t.co/8GNJvCFEci #Diabetes https://t.co/Cs6dMclFdW

  • Mashup Score: 4

    In this special edition episode, hosts break down what the announcement of the 10 drugs selected for Medicare price negotiations under the Inflation Reduction Act means for providers and people with diabetes.

    Tweet Tweets with this article
    • In this special edition episode of #DiabetesDialogue, @DianaMIsaacs and @Natalie_Bellini break down what the @HHSgov announcement of the 10 drugs selected for #Medicare price negotiations means for providers and people with #diabetes. https://t.co/SBNQ4M8PAE https://t.co/F1HKGx1sKn

  • Mashup Score: 1

    Less than 2 weeks after the release of their SELECT reaction podcast, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down for a special edition episode of Diabetes Dialogue to discuss STEP-HFpEF data and the implications for semaglutide 2.4 mg.

    Tweet Tweets with this article
    • Less than 2 weeks after releasing their SELECT reaction podcast, @DianaMIsaacs and @natalie_bellini sit down for a special edition episode of #DiabetesDialogue to discuss STEP-HFpEF data and the implications for semaglutide 2.4 mg. https://t.co/eVvChsGnRy #ESCCongress2023 https://t.co/Hzns8fRabk